Co-treatment of Bcr-AbI positive cells with imatinib mesylate and histone deacetylase inhibitor.

被引：0
|
作者：
Kawano, T [1 ]
Yamada, JH [1 ]
Yamada, H [1 ]
机构：
[1] Jikei Univ, Inst DNA Med, Tokyo, Japan
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6264S / 6264S
页数：1
相关论文
共 50 条
  • [1] SUCCESSFUL CO-TREATMENT OF BCR-ABL LEUKEMIC CELLS WITH PONATINIB, AN ABL KINASE INHIBITOR, AND VORINOSTAT, A HISTONE DEACETYLASE INHIBITOR: A POTENTIAL TREATMENT FOR BCR-ABL POSITIVE LEUKEMIA CELLS
    Okabe, S.
    Tauchi, T.
    Kimura, S.
    Maekawa, T.
    Ohyashiki, K.
    HAEMATOLOGICA, 2012, 97 : 210 - 210
  • [2] Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
    Zhang, Bin
    Strauss, Adam Campbell
    Chu, So
    Hoi, Yin Wei
    Snyder, David S.
    Huettner, Claudia
    Shultz, Lenny
    Holyoake, Tessa L.
    Bhatia, Ravi
    BLOOD, 2009, 114 (22) : 83 - 83
  • [3] Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxarmic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
    Nimmanapalli, R
    Fuino, L
    Stobaugh, C
    Richon, V
    Bhalla, K
    BLOOD, 2003, 101 (08) : 3236 - 3239
  • [4] Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    BLOOD, 2011, 118 (21) : 612 - 612
  • [5] An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with Mitomycin-C and a histone deacetylase inhibitor
    Tae-Hyun Kim
    Hyun Cheol Oh
    Young Hyun Yoo
    Jee Hyun Rho
    Woo Chan Park
    Hee Bae Ahn
    Woo Jin Jeung
    Sae Heun Rho
    Archives of Pharmacal Research, 2010, 33 : 1261 - 1267
  • [6] An Experimental Study of Rabbit Conjunctival Epithelial Toxicity Using Co-treatment with Mitomycin-C and a Histone Deacetylase Inhibitor
    Kim, Tae-Hyun
    Oh, Hyun Cheol
    Yoo, Young Hyun
    Rho, Jee Hyun
    Park, Woo Chan
    Ahn, Hee Bae
    Jeung, Woo Jin
    Rho, Sae Heun
    ARCHIVES OF PHARMACAL RESEARCH, 2010, 33 (08) : 1261 - 1267
  • [7] Co-treatment with aurora kinase inhibitor MK-0457 and pan-histone deacetylase inhibitor vorinostat: A novel targeted treatment for AML and CML
    Ustun, C.
    Fiskus, W.
    Wang, Y.
    Rao, R.
    Lee, P.
    Kolhe, R.
    Fernandez, P.
    Jillella, A. P.
    Buser, C.
    Bhalla, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances the cytotoxic effects of gleevee and arsenic trioxide (AT) against Ber-Abl positive human leukemia cells
    Bhalla, KN
    Nimmanapalli, R
    Stobaugh, C
    Fuino, L
    Richon, V
    BLOOD, 2002, 100 (11) : 270B - 270B
  • [9] Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Kitahara, Toshihiko
    Tanaka, Yoko
    Ohyashiki, Kazuma
    PLOS ONE, 2014, 9 (02):
  • [10] Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
    Zhang, Bin
    Strauss, Adam C.
    Chu, Su
    Li, Min
    Ho, Yinwei
    Shiang, Keh-Dong
    Snyder, David S.
    Huettner, Claudia S.
    Shultz, Leonard
    Holyoake, Tessa
    Bhatia, Ravi
    CANCER CELL, 2010, 17 (05) : 427 - 442
12345